ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,765Medicare Part D Prescriptions Filled, Including Refills

Rank: 98 out of 917

$599K Total Retail Price of All Prescriptions

Rank: 75 out of 917

758 Patients Receiving at Least One Drug in Part D
85%Patients 65 Years and Older
27% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Washington
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 758 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

11% of this provider’s 758 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 8,221 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

13 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Washington
LISINOPRIL 512 434 1 1
SIMVASTATIN 435 394 2 2
LEVOTHYROXINE SODIUM 348 289 3 3
METFORMIN HCL 343 303 4 8
HYDROCHLOROTHIAZIDE 320 273 5 9
AMLODIPINE BESYLATE 297 258 6 5
ATORVASTATIN CALCIUM 280 241 7 14
OMEPRAZOLE 260 218 8 4
METOPROLOL SUCCINATE 223 199 9 18
METOPROLOL TARTRATE 216 197 10 11
HYDROCODONE-ACETAMINOPHEN 194 149 S3 11 6
FUROSEMIDE 187 163 12 7
FLUTICASONE PROPIONATE 183 149 13 26
CITALOPRAM HBR 170 145 14 15
PRAVASTATIN SODIUM 168 161 15 20
WARFARIN SODIUM 152 133 16 10
LOSARTAN POTASSIUM 137 117 17 13
ATENOLOL 135 118 18 12
ALENDRONATE SODIUM 109 105 19 23
CRESTOR 102 82 20 30
GABAPENTIN 93 69 21 17
DIGOXIN 92 74 22 41
AZITHROMYCIN 92 79 22 61
POTASSIUM CHLORIDE 87 79 24 16
SPIRIVA 80 79 25 45
RANITIDINE HCL 78 54 26 29
TRAZODONE HCL 76 65 27 22
ZOLPIDEM TARTRATE 75 48 28 21
PROAIR HFA 74 42 29 35
GLIPIZIDE 69 54 30 40
FENOFIBRATE 64 64 31 73
ROPINIROLE HCL 63 58 32 88
ADVAIR DISKUS 61 52 33 47
FLUOXETINE HCL 60 53 34 38
ALLOPURINOL 59 40 35 31
LOVASTATIN 59 47 35 19
LISINOPRIL-HYDROCHLOROTHIAZIDE 59 56 35 42
CIPROFLOXACIN HCL 58 55 38 72
ACTOS 53 48 39 112
CARVEDILOL 53 25 39 33
PEN NEEDLE 52 35 41 99
SPIRONOLACTONE 52 45 41 55
PANTOPRAZOLE SODIUM 52 40 41 44
LYRICA 50 42 44 122
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 1, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.